Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Organon's gross profit for the
three
months ended in Jun. 2026 was $847 Mil. Organon's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $3,228 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Organon's gross profit for the
three
months ended in Jun. 2026 was $847 Mil. Organon's Revenue for the
three
months ended in Jun. 2026 was $1,558 Mil. Therefore, Organon's Gross Margin % for the quarter that ended in Jun. 2026 was 54.36%.
Organon had a gross margin of 54.36% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 8 years, the highestGross Margin % of Organon was 70.76%. The lowest was 52.00%. And the median was 61.03%.
Warning Sign:
Organon & Co gross margin has been in long-term decline. The average rate of decline per year is -4%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Organon had a gross margin of 54.36% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Organon Gross Profit Related Terms
Organon Gross Profit Historical Data
* Premium members only.
The historical data trend for Organon's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Organon's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's Gross Profit distribution charts can be found below:
* The bar in red indicates where Organon's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,228 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Organon (OGN) has a Gross Profit of $3,228 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Organon and its competitors.
Is Organon's Gross Profit too high?
Organon's current Gross Profit is $3,228 Mil. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Gross Profit compare to AMRN and SCLX?
Organon's Gross Profit of $3,228 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Organon and its competitors. Organon's current Gross Profit is $3,228 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $13.38, compared to a current price of $13.60 — trading 1.6% above its estimated fair value. The current Gross Profit is $3,228 Mil. Organon's overall GF Score™ is 71/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Organon (OGN), the current Gross Profit is $3,228 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be overvalued.
The current stock price of $13.60 is trading 1.6% above its estimated GF Value™ of $13.38.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
Gross Profit: $3,228 Mil
GF Value™: $13.38 vs. price of $13.60 (1.6% above fair value)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
